The Journal of family practice
-
The gut microbiome, sometimes referred to as the "organ" we do not know we have, is a dynamic ecosystem that plays an important role in human health and disease. Alterations in the gut microbiome (dysbiosis) are associated with wide-ranging disease states, including metabolic diseases like type 2 diabetes mellitus (T2D). Growing evidence suggests improved gut microbiome composition from targeted microbiome interventions leads to improvement in glycemic control in patients with T2D.
-
At the end of the activity, participants will be able to:Summarize important findings and trends involving women and atherosclerotic cardiovascular disease (ASCVD). Characterize the multiple cardiometabolic changes that occur during menopause and the associated ASCVD risk. Discuss the challenges of assessing ASCVD risk and dyslipidemia management in women. Identify women with elevated ASCVD risk and implement guideline-recommended statin therapy.
-
The increasing prevalence of type 1 diabetes (T1D) suggests family physicians will regularly see first-degree relatives of patients with T1D with the genetic propensity for developing T1D. T1D autoantibody screening by family clinicians addresses an important need to identify at-risk individuals early and achieve short- and long-term health benefits. Multiple T1D screening options and programs are available to clinicians that provide patient education, testing, result analysis, follow-up, and opportunity for participation in T1D prevention trials. The provider-patient relationship in family medicine places clinicians in a unique position to provide monitoring and followup crucial to family members with positive autoantibody results.
-
Following these guidelines to order fewer tests can improve health care quality and patient experience, while reducing wasteful costs.
-
At the end of the activity, participants will be able to:Describe the burden of disease and risk of atherothrombotic events in patients with polyvascular disease-peripheral arterial disease (PAD) and coronary artery disease (CAD). Implement screening and diagnostic procedures to improve detection of polyvascular disease and accurately assess overall atherothrombotic risk. Select evidence-based treatment to reduce cardiovascular and limb events in patients with polyvascular disease.